Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer

[1]  Jay Shendure,et al.  Genome interrupted: sequencing of prostate cancer reveals the importance of chromosomal rearrangements , 2011, Genome Medicine.

[2]  A. Chinnaiyan,et al.  Disruptive events in the life of prostate cancer. , 2011, Cancer cell.

[3]  Hailong Wu,et al.  MicroRNA-101-mediated Akt activation and estrogen-independent growth , 2011, Oncogene.

[4]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[5]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[6]  Yi Lu,et al.  Novel diagnostic biomarkers for prostate cancer , 2010, Journal of Cancer.

[7]  M. Shen,et al.  Molecular genetics of prostate cancer: new prospects for old challenges. , 2010, Genes & development.

[8]  S. Srivastava,et al.  Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer , 2010, Clinical Cancer Research.

[9]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[10]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[11]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[12]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[13]  Xiumei Cai,et al.  MAGI-2 Inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells. , 2007, Archives of biochemistry and biophysics.

[14]  J. Schalken,et al.  Molecular markers for prostate cancer. , 2007, Cancer letters.

[15]  M. Gleave,et al.  NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. , 2006, Cancer cell.

[16]  L. Marks,et al.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. , 2006, Clinical chemistry.

[17]  G. Horgan,et al.  Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .

[18]  R. Cardiff,et al.  Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[20]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[21]  K. Tsuchida,et al.  Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. , 2001, Cancer research.

[22]  C. Ross,et al.  Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Bissell.  A First-Generation Multiplex Biomarker Analysis of Urine For The Early Detection of Prostate Cancer , 2009 .

[24]  P. Cheng,et al.  Downregulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli , 2004, Molecular and Cellular Biochemistry.